| Literature DB >> 20226042 |
Grace M Lee1, Joshua A Salomon, Charlene Gay, James K Hammitt.
Abstract
BACKGROUND: A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents' preferences for different relevant health outcomes. Our objectives were to: (1) describe parent preferences for GAS disease and vaccination using willingness-to-pay (WTP) and time trade-off (TTO) methods; and (2) understand how parents' implied WTP for a quality-adjusted life year (QALY) gained might vary depending on the particular health outcome considered (e.g. averted GAS disease vs. vaccine adverse events).Entities:
Mesh:
Substances:
Year: 2010 PMID: 20226042 PMCID: PMC2848145 DOI: 10.1186/1477-7525-8-28
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Characteristics of respondents (N = 119)
| N (%) | |
|---|---|
| Age of respondent (in quartiles) (N = 118) | |
| 19-36 years | 29 (24.6%) |
| 37-40 years | 32 (27.1%) |
| 41-43 years | 26 (22.0%) |
| 44-62 years | 31 (26.3%) |
| Female respondent (N = 119) | 108 (90.8%) |
| Annual household income, 2005 US$ (N = 119) | |
| <50,000 | 26 (21.9%) |
| 50,000-<80,000 | 22 (18.5%) |
| > = 80,000 | 60 (50.4%) |
| Refused to answer | 11 (9.2%) |
| Educational level (N = 117) | |
| Up to high school graduate | 22 (18.8%) |
| Some college/technical school | 29 (24.8%) |
| College graduate | 40 (34.2%) |
| Postgraduate | 26 (22.2%) |
| Race/ethnicity (N = 117) | |
| White | 91 (77.8%) |
| African American | 16 (13.7%) |
| Hispanic | 4 (3.4%) |
| Other | 6 (5.1%) |
| Survey version (N = 119) | |
| Low opening bids | 40 (33.6%) |
| Intermediate opening bids | 41 (34.5%) |
| High opening bids | 38 (31.9%) |
Median open-ended WTP (N = 100) and TTO (N = 96) values for health states associated with Group A Streptococcal disease and vaccination.
| Health state | Median WTP | Median undiscounted days traded (25%-75%) | Median days traded discounted at 3% (25%-75%) | Median days traded discounted at 5% (25%-75%) |
|---|---|---|---|---|
| Local reaction | $30 (10-50) | 0.42 (0.15-1.0) | 0.12 (0.04-0.33) | 0.05 (0.01-0.16) |
| Systemic reaction | $50 (20-50) | 0.83 (0.19-1.83) | 0.22 (0.05-0.43) | 0.10 (0.02-0.19) |
| Impetigo | $75 (35-112.5) | 1.25 (0.42-7.0) | 0.41 (0.11-1.99) | 0.21 (0.04-0.78) |
| Strep throat | $75 (30-150) | 2.5 (0.50-10.0) | 0.75 (0.15-3.61) | 0.33 (0.07-1.83) |
| Septic arthritis | $1,000 (250-2,250) | 21.0 (8.5-120.0) | 6.56 (3.03-32.71) | 2.98 (1.17-12.6) |
| Toxic shock syndrome | $3,000 (1,000-10,000) | 90.0 (30.0-365.0) | 31.0 (7.56-135.65) | 14.2 (3.15-63.9) |
Figure 1Median (IQR) WTP per QALY.